Retatrutide for Weight Loss: What Rochester, NY Patients Should Know
If you’ve been researching weight loss medications in Rochester, NY, you’ve probably heard about GLP-1 medications such as semaglutide and tirzepatide. Now another name is generating significant attention: retatrutide.
Retatrutide is an investigational weight loss medication being developed by Eli Lilly. Early and Phase 3 clinical trial results have generated interest because of the amount of weight loss seen in some participants.
But there is an important distinction patients need to understand:
Retatrutide is not currently FDA approved and is not available as an approved prescription weight loss medication.
Here’s what we know so far and what patients considering medical weight loss in Rochester should understand.
What Is Retatrutide?
Retatrutide is a once-weekly injectable medication currently being studied for obesity, type 2 diabetes and several obesity-related health conditions.
What makes retatrutide different is that it targets three hormone receptors:
- GLP-1
- GIP
- Glucagon
This is why retatrutide is often referred to as a triple agonist.
You may also see retatrutide called a “GLP-3” medication online. That isn’t technically accurate. There is no GLP-3 hormone involved. The nickname comes from retatrutide targeting three different receptors.
How Is Retatrutide Different From Semaglutide and Tirzepatide?
The major difference is the number of pathways each medication targets.
Semaglutide acts primarily on the GLP-1 receptor.
Tirzepatide targets both GIP and GLP-1 receptors.
Retatrutide targets GIP, GLP-1 and glucagon receptors.
Researchers are studying whether targeting all three pathways may have additional effects on appetite, metabolism, blood sugar regulation and energy expenditure.
However, newer does not automatically mean better for every patient. The appropriate medication depends on a patient’s medical history, goals, laboratory results, response to treatment and other individual factors.
How Much Weight Are People Losing With Retatrutide?
The Phase 3 results have received considerable attention.
In the TRIUMPH-1 study, participants receiving the 12 mg dose lost an average of approximately 28.3% of their body weight over 80 weeks. Among participants with a starting BMI of 35 or higher who continued into an extension, average weight loss reached approximately 30.3% at 104 weeks.
Those are averages from a controlled clinical trial and should not be interpreted as a guarantee of individual results.
Additional Phase 3 studies have also reported significant weight reduction in participants with obesity and type 2 diabetes and in individuals with severe obesity and established cardiovascular disease.
Is Retatrutide FDA Approved?
No.
As of September 2026, retatrutide remains an investigational medication and has not been approved by the FDA.
Eli Lilly has announced plans to submit retatrutide for U.S. regulatory approval in 2027.
That means legitimate retatrutide is currently available only through authorized clinical trials.
Be Careful With “Retatrutide” Being Sold Online
This is especially important.
Despite retatrutide not being FDA approved, products claiming to contain retatrutide are already being marketed online and through some businesses.
Patients should be extremely cautious.
The manufacturer states that retatrutide cannot currently be legally sold to patients outside its clinical trials. Products marketed as “research peptides” or compounded retatrutide have not gone through the same manufacturing, safety and regulatory processes as an FDA-approved medication.
When considering any medical weight loss medication, treatment should begin with an evaluation from a qualified healthcare provider rather than purchasing an injectable product online.
What About Side Effects?
Because retatrutide is still being studied, researchers continue to evaluate its complete safety profile.
As with other medications that affect GLP-1 pathways, gastrointestinal side effects have been among those observed during clinical trials.
This is another reason medical supervision matters. Weight loss medications should not simply be selected based on which medication appears to produce the largest percentage of weight loss.
Your overall health, medical history, nutrition, muscle mass, laboratory results and ability to tolerate treatment all matter.
Retatrutide, GLP-1s and Muscle Loss
As weight loss medications become more effective, body composition becomes increasingly important.
Losing 20, 30 or even more pounds isn’t necessarily the entire goal.
What are you losing?
During significant weight loss, patients can lose both body fat and lean muscle mass. Preserving muscle is important for strength, function, metabolism and long-term weight management.
That’s why a comprehensive medical weight loss program should also focus on:
- Adequate protein intake
• Resistance and strength training
• Proper hydration
• Appropriate calorie and nutrient intake
• Sleep and recovery
• Monitoring progress beyond the number on the scale
The goal should be losing excess body fat while preserving as much lean muscle as possible.
What Weight Loss Medications Are Available Now?
You don’t necessarily need to wait for the next generation of medications to begin addressing your weight.
FDA-approved weight management medications are already available, and the right treatment varies from person to person.
A medical weight loss evaluation can help determine whether medication is appropriate and which options should be considered based on your individual health and goals.
Medical Weight Loss in Rochester, NY
At Vitalize Medical & Aesthetics in Rochester, NY, medical weight loss isn’t about simply prescribing an injection and sending you home.
Treatment begins with an evaluation so your provider can better understand your health, goals and whether medical weight loss is appropriate for you.
As medications and research continue to evolve, our focus remains the same: helping patients approach weight management safely, medically and with long-term health in mind.
If you’re searching for GLP-1 weight loss in Rochester, NY, have questions about semaglutide or tirzepatide, or want to learn more about medically supervised weight loss, contact Vitalize Medical & Aesthetics to schedule a consultation.
Retatrutide is investigational and is not FDA approved. Vitalize Medical & Aesthetics does not currently offer retatrutide. This article is for educational purposes only and should not be considered medical advice.